Cite
HARVARD Citation
Hu, Q. et al. (2020). Optimum duration of adjuvant trastuzumab in treatment of human epidermal growth factor receptor-2 positive early breast cancer: protocol for a network meta-analysis of randomised controlled trials. BMJ open. 10 (11), p. . [Online].